EDIT Competitors & Alternatives

Compare Editas Medicine Inc with similar stocks in the same industry

Biotechnology

EDIT

Main Stock
$1.91
-12.21%
Tradestie Score
51
Market Cap
$319.22M
Revenue Growth
37.4%
Analyst Upside
+220.2%

Supply-Chain & Ecosystem Map (Customers, Suppliers & Direct Competitors)

Bottleneck Score: 7/10 Genomics Precision Med Crispr Gene Editing
Competitive Moat: Oligopoly
Core Technology Stack: CRISPR-Cas9, Gene editing therapies
Major Customers 2
Academic research institutions Pharmaceutical partners
Critical Suppliers 2
Contract manufacturing organizations CRISPR component suppliers
Direct Ecosystem Rivals 3

Top Competitors

216 stocks in Biotechnology
Company Price Market Cap P/E Score Action
DRTS Alpha Tau Medical Ltd. Ordinary Shares
$12.09
-9.64%
$371.64M - 50 Compare
CAPR Capricor Therapeutics Inc
$8.47
-11.12%
$357.51M - 28 Compare
DMAC DiaMedica Therapeutics Inc. Common Stock
$8.42
-4.27%
$354.59M - 48 Compare
CGEM Cullinan Therapeutics, Inc. Common Stock
$9.72
-5.45%
$354.45M - 47 Compare
LBRX LB Pharmaceuticals Inc Common Stock
$42.85
-0.37%
$353.70M - 36 Compare
ANNX Annexon, Inc. Common Stock
$3.59
-8.55%
$332.96M - 46 Compare
REPL Replimune Group, Inc.
$21.54
-1.60%
$328.62M - 26 Compare
EPRX Eupraxia Pharmaceuticals Inc. Common Stock
$7.46
-8.47%
$307.12M - 32 Compare
CADL Candel Therapeutics, Inc. Common Stock
$6.13
-1.21%
$304.12M - 47 Compare
JBIO Jade Biosciences, Inc. Common Stock
$15.34
-4.96%
$297.23M - 36 Compare

Data updated: Nov 16, 2026 | Industry: Biotechnology (SIC 2836)

216 stocks in this industry